

JFW

Please Direct All Correspondence to Customer Number 20995



TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Andersson, et al.
 App. No : 10/623,119
 Filed : July 17, 2003
 For : MUSCARINIC AGONISTS
 Examiner : unknown
 Art Unit : 1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 9, 2005

(Date)



 Sam K. Tahmassebi, Reg. No. 45,151
Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing 7 references.
 - (X) Enclosing 2 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


 Sam K. Tahmassebi
 Registration No. 45,151
 Attorney of Record
 Customer No. 20,995
 (619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Andersson, et al.
 App. No : 10/623,119
 Filed : July 17, 2003
 For : MUSCARINIC AGONISTS
 Examiner : Unknown
 Art Unit : 1614

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 7 references to be considered by the Examiner. Also enclosed are 2 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that entries 6 and 7 contained in this Statement were first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

June 9, 2005

By:

Sam K. Tahmassebi

Registration No. 45,151

Attorney of Record

Customer No. 20,995

(619) 235-8550

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 9, 2005

(Date)


Sam K. Tahmassebi, Reg. No. 45,151



INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/623,119
<i>(Multiple sheets used when necessary)</i>		Filing Date	July 17, 2003
		First Named Inventor	Andersson, et al.
		Art Unit	1614
SHEET 1 OF 1		Examiner	Unknown
		Attorney Docket No.	ACADIA.011DV1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number <i>Number - Kind Code (if known)</i> Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US 5,494,908	02-27-1996	O'Malley et al.	
	2	US 5,580,982	12-03-1996	O'Malley et al	
	3	US 5,756,754	05-26-1998	O'Malley et al	
	4	US 5,925,766	07-20-1999	O'Malley et al	
	5	US 6,046,203	04-04-2000	O'Malley et al	

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document <i>Country Code-Number-Kind Code</i> Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	6	WO 94/12495	02-15-2003	Hoest-Russel Pharm. Inc.	T ¹

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ¹
	7	Davis, et al. 3-Substituted-1-2-Benzisoxazoles: Novel Antipsychotic Agents, Drug Design and Discovery, Vol 8, No. 3 1992, Harwood Academic Publishers GmbH, pp225-240; XP000608016.			

1761286
060905

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.